In IRI-AKI, treatment with SIRT1 activator, SRT1720 restores the expression of PGC-1α in kidneys, leading to enhanced mitochondria biogenesis characterized by the increase of mitochondrial mass and ATP levels, and improved renal function [103]. This evidence concerns the gene PPARGC1A and acute kidney injury.